文献速递炎症性肠病

克罗恩病患者皮下注射英夫利昔单抗生物类似药CT-P13后14天治疗周期内药物水平稳定

Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2022-02-28

本研究纳入20例病情处于临床-生物学缓解、正在接受英夫利昔单抗(IFX)静脉维持治疗的克罗恩病患者,转换为每2周皮下注射CT-P13 120 mg,在连续2个治疗周期内各进行3次访视(第4-6天、第7-9天、第14天)共120次评估。结果显示,个体内IFX血清药物水平变异较大,但每个周期内各访视点的中位药物水平相似;结论认为在CT-P13皮下维持治疗下,IFX药物水平在14天治疗周期内相当稳定,可在两次注射之间任何时间进行治疗药物监测。

要点

  • 20例克罗恩病患者共进行120次评估,IFX平均药物水平为11.3±4.9 μg/ml,中位10.9 μg/ml(IQR 7.5-15.5)。
  • A周期V1、V2、V3中位药物水平分别为11.1 μg/ml(7.8-14.5)、12.0 μg/ml(7.2-16.1)和11.0 μg/ml(7.5-15.1)。
  • B周期V1、V2、V3中位药物水平分别为11.6 μg/ml(7.9-14.9)、11.4 μg/ml(8.1-15.2)和10.9 μg/ml(7.9-15.6)。

核心结论

  • 在克罗恩病缓解期接受CT-P13皮下维持治疗的患者中,IFX药物水平在14天治疗周期内相当稳定,未出现谷浓度。

研究设计与样本

  • 研究纳入20例接受静脉IFX/CT-P13维持治疗且处于临床-生物学缓解的克罗恩病患者,在末次输注8周后转换为CT-P13皮下注射120 mg每2周一次,自开始皮下注射8周后起,在连续2个治疗周期(周期A和B)各进行3次访视(第4-6天、第7-9天、第14天),共120次评估。

主要发现

  • 观察到个体内IFX血清药物水平变异较大;汇总120次评估,平均药物水平为11.3±4.9 μg/ml,中位10.9 μg/ml(IQR 7.5-15.5)。
  • 周期A中位药物水平在V1、V2、V3分别为11.1 μg/ml(7.8-14.5)、12.0 μg/ml(7.2-16.1)、11.0 μg/ml(7.5-15.1)。
  • 周期B中位药物水平在V1、V2、V3分别为11.6 μg/ml(7.9-14.9)、11.4 μg/ml(8.1-15.2)、10.9 μg/ml(7.9-15.6)。
  • 单因素分析未能识别出低药物水平的预测因素。

关键数值与推荐

  • CT-P13皮下注射剂量为120 mg每2周一次。
  • 自开始CT-P13皮下注射8周后开始评估,每个周期访视时间为第4-6天(访视1)、第7-9天(访视2)和第14天(访视3),第1天和第14天为皮下注射日。

临床怎么用

  • 在病情不活动的克罗恩病患者接受CT-P13皮下维持治疗期间,IFX治疗药物监测可在两次CT-P13皮下注射之间的任何时间进行。

局限性

  • 单因素分析未能识别出低药物水平的预测因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The new subcutaneous (sc) formulation of the infliximab (IFX) biosimilar CT-P13 results in homogeneous serum trough concentrations of IFX at steady state. The present study aimed to investigate in Crohn's disease (CD) patients the intra-individual variations of IFX drug levels at multiple time-points during 2 consecutive cycles of maintenance therapy with CT-P13 sc. PATIENTS AND METHODS: CD patients in clinico-biological remission under maintenance therapy with intravenous (iv) IFX/CT-P13 were switched to CT-P13 sc 8 weeks (W) after the last infusion. They were treated with CT-P13 sc, 120 mg every 2 W. Assessments were performed from 8 W after starting CT-P13 sc and patients had to attend 6 visits on 2 consecutive cycles of treatment (cycles A and B). Visits were scheduled on days 4-6 (visit 1), days 7-9 (visit 2) and day 14 (visit 3) of each cycle, where days 1 and 14 were the days of sc injection of CT-P13. At each visit, peripheral blood was collected to measure serum IFX levels and anti-drug antibodies. RESULTS: Twenty patients underwent 120 evaluations. Large intra-individual variations of serum drug levels of IFX were observed. When pooling the 120 evaluations, the mean drug level was 11.3 ± 4.9 μg/ml, and the median drug level was 10.9 μg/ml (IQR 7.5-15.5). During each cycle, the median drug levels were similar between visits 1 and 2 as well as between visits 1 and 3 and between visits 2 and 3. In cycle A, median drug levels were 11.1 μg/ml (7.8-14.5), 12.0 μg/ml (7.2-16.1) and 11.0 μg/ml (7.5-15.1) at V1, V2 and V3, respectively. Similar results were obtained in cycle B, where median drug levels were 11.6 μg/ml (7.9-14.9), 11.4 μg/ml (8.1-15.2) and 10.9 μg/ml (7.9-15.6) at V1, V2 and V3, respectively. In univariate analysis, we failed to identify factors predictive of low drug levels. CONCLUSIONS: IFX drug levels are quite stable within 14-day treatment cycle, without trough levels in CD patients in remission during the maintenance therapy with CT-P13 sc. In patients with inactive CD under maintenance therapy with CT-P13 sc, therapeutic drug monitoring of IFX can be performed at any time between two CT-P13 sc injections.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Roblin X, Veyrard P, Bastide L, et al. Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease. Aliment Pharmacol Ther. 2022. PMID: 35229331. doi:10.1111/apt.16852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。